Research Analysts Set Expectations for TLX FY2025 Earnings

Key Points

• William Blair has increased its FY2025 earnings per share (EPS) estimate for Telix Pharmaceuticals from $0.06 to $0.09, maintaining an "Outperform" rating on the stock.
• UBS Group has reduced its price target for Telix Pharmaceuticals from $23.00 to $20.00, while Citigroup started coverage with a "buy" rating and a $22.00 price objective.
• The current consensus estimate for Telix Pharmaceuticals' full-year earnings is $0.24 per share, with an average stock rating of "Moderate Buy" and a target price of $21.00.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Free Report) - Investment analysts at William Blair upped their FY2025 earnings per share (EPS) estimates for shares of Telix Pharmaceuticals in a research note issued on Tuesday, October 14th. William Blair analyst A. Hsieh now forecasts that the company will post earnings per share of $0.09 for the year, up from their previous forecast of $0.06. William Blair has a "Outperform" rating on the stock. The consensus estimate for Telix Pharmaceuticals' current full-year earnings is $0.24 per share. William Blair also issued estimates for Telix Pharmaceuticals' FY2026 earnings at $0.20 EPS.

Several other equities analysts have also recently weighed in on TLX. UBS Group cut their price target on Telix Pharmaceuticals from $23.00 to $20.00 and set a "buy" rating for the company in a report on Tuesday, September 23rd. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Telix Pharmaceuticals in a research note on Wednesday, October 8th. Citigroup started coverage on Telix Pharmaceuticals in a research note on Thursday, September 18th. They issued a "buy" rating and a $22.00 price objective for the company. Canaccord Genuity Group raised Telix Pharmaceuticals to a "strong-buy" rating in a research note on Monday, October 6th. Finally, JPMorgan Chase & Co. reaffirmed a "neutral" rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 28th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $21.00.

Telix Pharmaceuticals Stock Performance

NASDAQ TLX opened at $11.01 on Thursday. The business has a 50 day simple moving average of $10.33 and a two-hundred day simple moving average of $14.20. Telix Pharmaceuticals has a 1-year low of $8.93 and a 1-year high of $30.36.

Institutional Investors Weigh In On Telix Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Private Advisor Group LLC bought a new stake in shares of Telix Pharmaceuticals during the 1st quarter worth approximately $170,000. ABC Arbitrage SA purchased a new position in Telix Pharmaceuticals during the 1st quarter worth $451,000. Russell Investments Group Ltd. purchased a new position in Telix Pharmaceuticals during the 2nd quarter worth $975,000. Jane Street Group LLC purchased a new position in Telix Pharmaceuticals during the 2nd quarter worth $564,000. Finally, IHT Wealth Management LLC purchased a new position in Telix Pharmaceuticals during the 2nd quarter worth $213,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.